

December 9, 2021  
Sawai Pharmaceutical Co., Ltd.

## Sawai Announces Listing of Five Generic Drugs with Nine Strengths

Osaka, Japan – December 9, 2021 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the listing of five generic drugs with nine strengths in the NHI (National Health Insurance) drug price list. Sawai's product line now includes 331 compounds with 817 strengths.

### The list of new products:

#### 1. Levetiracetam Tablets, Granular Tablets, DS

Generic name:	Levetiracetam	Strengths:	Tablets, Granular Tablets: 250mg, 500mg, DS: 50%
Brand products:	E Keppra® Tablets 250mg, 500mg, E Keppra® Dry syrup 50%		

#### 2. Ambrisentan Tablets

Generic name:	Ambrisentan	Strengths:	Tablets: 2.5mg
Brand products:	Volibris Tablets 2.5mg		

#### 3. Olopatadine Ophthalmic Solution

Generic name:	Olopatadine	Strengths:	Ophthalmic Solution: 0.1%
Brand products:	Patanol® Ophthalmic Solution 0.1%		

#### 4. Iguratimod Tablets

Generic name:	Iguratimod	Strengths:	Tablets: 25mg
Brand products:	Careram® Tablets 25 mg		

#### 5. Bortezomib Injection

Generic name:	Bortezomib	Strengths:	Injection: 3mg
Brand products:	VELCADE® Injection 3mg		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

◆ Contact Information ◆

Public Relations Office, Sawai Pharmaceutical Co., Ltd.  
E-mail : [koho@sawai.co.jp](mailto:koho@sawai.co.jp)